Quantcast

Latest BPH Stories

2009-03-24 06:04:00

SOUTHAMPTON, England, March 24 /PRNewswire/ -- - VA106483 Completes Phase IIa Trial and VA111913 Completes Phase I Dosing Vantia Therapeutics, a company focusing on first-in-class therapies for unmet medical needs, announces further clinical trial progress with its two lead development compounds, VA106483 for nocturia associated with benign prostatic hypertrophy (BPH) and VA111913 for dysmenorrhoea. The Phase IIa trial of VA106483 has completed, while dosing is complete in the...

2009-03-11 05:51:00

All amounts are in U.S. dollars QUEBEC CITY, March 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) ("the Company"), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the fourth quarter and the full year ended December 31, 2008. 2008 Highlights - February - First patients treated with AEZS-108 for a Phase 2 trial in advanced ovarian and endometrial cancers. -...

2009-03-06 06:11:00

Development and Commercialization for Cetrorelix Pamoate in Benign Prostatic Hyperplasia BRIDGEWATER, N.J., March 6 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today the signing of an agreement with AEterna Zentaris GmbH for the development, registration and marketing of cetrorelix pamoate, a luteinizing hormone-releasing hormone (LHRH) antagonist, for the treatment of benign prostatic hyperplasia (BPH), in the U.S. Cetrorelix pamoate, a long-acting intramuscular injection, is...

2009-03-06 06:00:00

All amounts are in US dollars QUEBEC CITY, March 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the signing of a development, commercialization and licensing agreement with sanofi-aventis (EURONEXT: SAN; NYSE: SNY) for the development, registration and marketing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market. Cetrorelix, a luteinizing...

2008-12-11 06:30:00

QUEBEC CITY, Dec. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported it has reached its goal of recruiting 500 patients for the safety study of the Phase 3 program in benign prostatic hyperplasia (BPH) with its flagship product candidate, cetrorelix, a novel investigational luteinizing hormone-releasing hormone (LHRH) antagonist. This safety trial, the third of three Phase 3...

2008-11-12 12:00:07

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce positive new results from the Company's most recent study of NX-1207, its drug in development for benign prostatic hyperplasia (BPH). A total of 67 patients and controls in this multi-center U.S. study consisting of 92% of eligible patients were followed for an average of 59 weeks after a single administration of NX-1207. Of the patients given full dose NX-1207, 76.7% required no further treatment compared to 37.5% for...

2008-10-30 12:00:21

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that data about the progress of Nymox's drug development for NX-1207, the Company's investigational drug for benign prostatic hyperplasia (BPH), were presented this morning at the 84th Annual Meeting of the Western Section of the American Urological Association being held in Monterey, CA. Barrett Cowan, MD, FACS, of Denver made the podium presentation. Dr. Cowan is an independent clinical investigator who has participated...

2008-10-28 12:00:17

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that recent results of clinical studies of NX-1207, the Company's investigational drug for the treatment of benign prostatic hyperplasia (BPH) or enlarged prostate, will be presented this Thursday at the 84th Annual Meeting of the Western Section of the American Urological Association being held in Monterey, California. The podium presentation will be given by Dr. Barrett Cowan of Denver. Dr. Cowan is an independent clinical...

2008-10-23 09:00:10

SEATTLE and GENEVA, Oct. 23 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation today presented preclinical data on its lead small molecule candidate, D-3263, which targets Trp-p8 (a transmembrane cation channel protein also known as Trp-M8), supporting Trp-p8 as a therapeutic cancer target. The poster, titled, "Preclinical Validation of the TrpM8 Ion Channel as a Cancer/ Benign Prostate Hyperplasia Target," was presented at the European Organization for Research and Treatment...

2008-10-22 12:00:16

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company's latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH), is nearing completion. The Company anticipates the reporting of final results and statistical analysis for the study within the next 2-3 weeks. The new study concerns assessment of the one year efficacy effects of a single treatment of NX-1207. NX-1207 has entered its Phase 3...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related